Credit Suisse’s ABVC BioPharma ABVC Stock Holding History

Credit Suisse’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,171	Closed	-$27K	–	4472
2021 Q3	$27K	Buy	+1,171	New	+$33.2K	﹤0.01%	4361

Other funds holding ABVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's ABVC Position: Q4 2021 in Review

Credit Suisse sold out of ABVC BioPharma (ABVC) in Q4 2021, closing a stake of 1,171 shares — an estimated $27K sold.

Credit Suisse first reported a position in ABVC in Q3 2021 and held it in 1 quarter. The position peaked at $27K in Q3 2021. 5 funds tracked by Wall St. Rank hold ABVC as of Q4 2021.

Credit Suisse reported no remaining ABVC BioPharma position as of Q4 2021 after selling out during the quarter.
Credit Suisse sold 1,171 ABVC BioPharma shares in Q4 2021, an estimated $27K.
Credit Suisse first reported a position in ABVC BioPharma in Q3 2021 and held it in 1 quarter.
Credit Suisse's ABVC BioPharma position peaked at $27K in Q3 2021.
5 funds tracked by Wall St. Rank held ABVC BioPharma as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.